STARHEALTH Star Health and Allied Insurance Company Q3 FY25 results (Oct–Dec 2024) and concall
Star Health reported a quarter marked by strong top-line growth in fresh premiums and retail segments, despite significant regulatory accounting transitions (1/N framework). While loss ratios remain elevated due to medical inflation and increased surgical frequencies, management has aggressively re-priced 65% of its retail portfolio to mitigate these pressures. The company continues to dominate the retail health space with a 32.2% market share and is pivoting towards an IFRS-aligned reporting structure.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 4,058 | 4,146 |
| EBITDA | 147 | 285 |
| Net profit | 111 | 215 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
